Bladder Cancer at a Crossroads: Sequencing, Biomarkers, and Combination Therapy

An expert panel convened to discuss the evolving treatment and diagnostic landscape of NMIBC. Moderated by Sia Daneshmand, MD, University of Southern California, the roundtable consisted of Mark D. Tyson, MD, Mayo Clinic; Aaron Berger, MD, Associated Urological Specialists; and Vignesh T. Packiam, MD, Rutgers Cancer Institute.

In the first segment of the discussion, the panel discusses a wave of bladder cancer therapies—including cretostimogene, gem/doce, and AI-driven biomarkers—highlighting the excitement around new data, treatment sequencing, and the potential of combination strategies to improve bladder preservation.

Advertisement

Latest News

Advertisement
Advertisement
Editorial Advisory Board

The Uromigos Live and Unplugged 2024

The Uromigos Live & Unplugged 2024

The Uromigos Live & Unplugged 2024 took place September 27-29 in Nashville, Tennessee.

This meeting was the third annual in-person event hosted by Thomas Powles, MD, and Brian Rini, MD, FASCO, in partnership with Mashup Media, featuring expert panels and audience discussion around the latest data in genitourinary oncology and vision for the future.

Expert Interviews

Conference Coverage

Live meeting highlights

David Canes, MDUrothelial Carcinoma | May 7, 2025
Dr. Canes discusses the formation of the WellPrept delivery platform and how it aims to boost patient education.
Mohummad Siddiqui, MDUrothelial Carcinoma | May 5, 2025
Mohummad Siddiqui, MD, discusses his work with the Commission on Cancer and their development on standards of care.
John Sfakianos, MDUrothelial Carcinoma Diagnostics | May 5, 2025
John P. Sfakianos, MD, discusses the history and use of ctDNA in the GU oncology field.
Victor Sandoval, MD, MScLocalized Renal Cell Carcinoma | May 5, 2025
Dr. Sandoval chats with David Ambinder, MD, on the upstaging of cT1b and cT2 tumors to pT3a.